Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors

References

• . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Israili ZH. Advances in the treatment of type 2 diabetes mellitus [published online ahead of print October 14, 2009]. Am J Ther. doi: 10.1097/MJT.0b013e3181afbf51
   Google Scholar
• . Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes. West Islip, NY: Professional Communications, Inc.; 2007
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . American Association of Clinical Endocrinologists. State of diabetes complications in America: a comprehensive report issued by the American Association of Clinical Endocrinologists. 2007. http://multivu.prnewswire.com/mnr/AACE/2007/docs/Diabetes_Complications_Report.pdf. Accessed April 2, 2010
   Google Scholar
• . Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation. 2008;117(4):574–584
   PubMed Web of Science ®Google Scholar
• . Blevins T. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Postgrad Med. 2010;122(1):172–183
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):541–559
   Web of Science ®Google Scholar
• . DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Blonde L, Rosenstock J, Triplitt C. What are incretins, and how will they influence the management of type 2 diabetes? J Manag Care Pharm. 2006;12(7 suppl A):S2–S12
   Web of Science ®Google Scholar
• . Spijkerman AM, Dekker JM, Nijpels G, . Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care. 2003;26(9):2604–2608
   PubMed Web of Science ®Google Scholar
• . Partanen J, Niskanen L, Lehtinen J, . Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(2):89–94
   PubMed Web of Science ®Google Scholar
• . Martin S, Schramm W, Schneider B, . Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes. 2007;115(8):495–501
   PubMed Web of Science ®Google Scholar
• . Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: an overshadowed association. Curr Opin Endocrinol Diabetes Obes. 2009;16(6):435–445
   PubMedGoogle Scholar
• . Resnick HE, Foster GL, Bardsley J, . Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531–537
   PubMed Web of Science ®Google Scholar
• . Kerr EA, Heisler M, Krein SL, . Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med. 2007;22(12):1635–1640
   PubMed Web of Science ®Google Scholar
• . Hivert MF, Warner AS, Shrader P, . Diabetes risk perception and intention to adopt healthy lifestyles among primary care patients. Diabetes Care. 2009;32(10):1820–1822
   Google Scholar
• . Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26(3):249–262
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32
   PubMed Web of Science ®Google Scholar
• . Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470
   PubMed Web of Science ®Google Scholar
• . Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb/ Wilmington, DE: AstraZeneca; 2009
   Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2009
   Google Scholar
• . Khoo J, Rayner CK, Jones KL, Horowitz M. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag. 2009;5(3):683–698
   PubMedGoogle Scholar
• . Ahrén B, Pacini G, Tura A, . Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res. 2007;39(11):826–829
   PubMed Web of Science ®Google Scholar
• . Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-4 inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936–1940
   PubMed Web of Science ®Google Scholar
• . Henry R, Smith S, Schwartz S, List JF, Duan Y, Chen R. β-cell stimulation by saxagliptin in patients with type 2 diabetes. Diabetes. 2009;58( suppl 1):447-P
   Google Scholar
• . Wolf R, Frederich R, Fiedorek F, . Evaluation of CV risk in saxagliptin clinical trials. Diabetes. 2009;58( suppl 1):8-LB
   Google Scholar
• . Williams-Herman DE, Round E, Swern AS, . Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14
   PubMedGoogle Scholar
• . Shen L, Han J, Yushmanova I, . Cardiovascular safety of exenatide BID: an integrated-analysis from long-term controlled clinical trials in subjects with type 2 diabetes. Diabetologia. 2009;52( suppl 1):S298
   Web of Science ®Google Scholar
• . Bunck MC, Mari A, Corner A, . One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment. Diabetologia. 2009;52( suppl 1):S7
   Web of Science ®Google Scholar
• . LaSalle JR. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgrad Med. 2010;122(1):144–152
   PubMed Web of Science ®Google Scholar
• . Victoza [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2010
   Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators.Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, ; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Cobble M. DPP-4 inhibitors: a new therapeutic class for the treatment of type 2 diabetes. J Fam Pract. 2009. http://www.jfponline.com/supplements_cme.asp?id=8068. Accessed April 2, 2010
   Google Scholar
• . DeFronzo RA, Hissa M, Garber AJ, . The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Hollander P, Li J, Allen E, . Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators.Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–1568
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–745
   PubMed Web of Science ®Google Scholar
• . Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators.Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622
   PubMed Web of Science ®Google Scholar
• . Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987
   PubMed Web of Science ®Google Scholar
• . DeFronzo R, Hissa MN, Garber AJ, Duan RY, Ravichandran S, Chen R. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes. 2009;58( suppl 1):547-P
   Web of Science ®Google Scholar
• . Williams-Herman D, Seck T, Golm G, . Long-term efficacy with sitagliptin as monotherapy or add-on therapy to metformin: improvement in glycaemic control over 2 years in patients with type 2 diabetes. Diabetologia. 2009;52( suppl 1):S296
   Web of Science ®Google Scholar
• . Maheux P, Doucet J, Allen E, . Efficacy and safety of saxagliptin 5 mg once-daily therapy in elderly patients with type 2 diabetes mellitus. Diabetologia. 2009;52( suppl 1):S302
   Google Scholar
• . Barzilai, N. Sitagliptin reduces blood glucose in elderly type 2′s. Diabetes in Control Web site. http://www.diabetesincontrol.com/articles/diabetes-news/6326&Itemid=8. Accessed April 2, 2010
   Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. US Department of Health and Human Services. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed April 2, 2010
   Google Scholar
• . Food and Drug Administration, Center for Drug Evaluation and Research. Endocrinologic and metabolic drugs advisory committee meeting: summary minutes. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM192026.pdf. Accessed April 2, 2010
   Google Scholar
• . Bristol-Myers Squibb, AstraZeneca. Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes [press release]. March 10, 2010. http://www.news-medical.net/news/20100310/Bristol-Myers-Squibb-AstraZeneca-commence-SAVOR-TIMI-53-trial-of-ONGLYZA-for-type-2-diabetes.aspx. Accessed April 2, 2010
   Google Scholar
• . ClinicalTrials.gov. Merck & Co.; Duke Clinical Research Institute, Oxford Diabetes Trials Unit. Sitagliptin cardiovascular outcome study (TECOS). Bethesda (MD): National Library of Medicine (US). 2010- [cited 2010 Mar 22]. http://clinicaltrials.gov/ct2/show/NCT00790205. NLM Identifier: NCT00790205
   Google Scholar
• . Drucker DJ. The biology of incretin hormones. Cell Metab. 3(3):153–165
   PubMed Web of Science ®Google Scholar